ANTENGENE CORP. DL-0001 Total Assets
ANTENGENE CORP. DL-0001 total assets. Based on the latest financial reports, ANTENGENE CORP. DL-0001 (722) holds total assets worth €1.26 Billion EUR (≈ $1.47 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ANTENGENE CORP. DL-0001 market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ANTENGENE CORP. DL-0001 (2021–2025)
Total assets of ANTENGENE CORP. DL-0001 from 2021 to 2025. This chart illustrates how ANTENGENE CORP. DL-0001's total assets have evolved over time, based on quarterly financial data. See 722 stock price and chart for real-time trading data and today's change.
ANTENGENE CORP. DL-0001 - Asset Composition Analysis
ANTENGENE CORP. DL-0001 Total Assets Breakdown (December 2025)
ANTENGENE CORP. DL-0001 total assets breakdown as of December 2025. ANTENGENE CORP. DL-0001's total assets of €1.26 Billion consist of 62.3% current assets and 37.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 57.1% |
| Accounts Receivable | €27.47 Million | 2.2% |
| Inventory | €7.53 Million | 0.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.40 Million | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ANTENGENE CORP. DL-0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 722 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ANTENGENE CORP. DL-0001's current assets represent 62.3% of total assets in 2025, a decrease from 94.3% in 2021.
- Cash Position: Cash and equivalents constituted 57.1% of total assets in 2025, down from 88.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
ANTENGENE CORP. DL-0001 Competitors by Total Assets
Key competitors of ANTENGENE CORP. DL-0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ANTENGENE CORP. DL-0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 6.53 | 5.72 |
| Quick Ratio | 2.94 | 6.44 | 5.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €519.20 Million | €809.83 Million | €918.24 Million |
ANTENGENE CORP. DL-0001 - Advanced Valuation Insights
This section examines the relationship between ANTENGENE CORP. DL-0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.59 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | €1.26 Billion |
| Market Capitalization | $225.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values ANTENGENE CORP. DL-0001's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ANTENGENE CORP. DL-0001's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual total assets of ANTENGENE CORP. DL-0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.26 Billion ≈ $1.47 Billion |
-6.52% |
| 2024-12-31 | €1.34 Billion ≈ $1.57 Billion |
-16.92% |
| 2023-12-31 | €1.62 Billion ≈ $1.89 Billion |
-24.44% |
| 2022-12-31 | €2.14 Billion ≈ $2.50 Billion |
-16.24% |
| 2021-12-31 | €2.56 Billion ≈ $2.99 Billion |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more